Peripheral Perfusion Targeted Fluid Management

January 3, 2014 updated by: ME van Genderen, Erasmus Medical Center

Peripheral Perfusion Targeted Fluid Management in Critically Ill Patients: a Pilot Study

  • Impaired peripheral perfusion is related to worse outcome in critically ill patients. Although this is known, these parameters have never been used as target for hemodynamic therapy.
  • We hypothesize that targeting of fluid administration on parameters of peripheral perfusion might prevent excessive fluid administration, leading to less formation of tissue edema, less respiratory dysfunction and shorter duration of mechanical ventilation in critically ill patients.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Rationale: Currently, fluid administration of critically ill patients is aimed at optimizing conventional hemodynamic parameters such as stroke volume and cardiac output. Fluid is infused repeatedly until patients become "non-responsive", i.e. cardiac output does not increase anymore. However, the ultimate goal of hemodynamic therapy should be to improve peripheral (i.e. tissue) perfusion. Recently we have shown that 1) increasing stroke volume does not always have an effect on peripheral perfusion and 2) that peripheral perfusion is not impaired when stroke volume can still be increased with fluid infusion. Furthermore, repeated administration of fluid in order to reach a maximum cardiac output can lead to an enormous accumulation of fluid in the patient. This leads to formation of lung edema and respiratory dysfunction and is associated with prolonged mechanical ventilation and ICU-stay. Recently, techniques have been developed which allow bedside assessment of peripheral perfusion. Although impaired peripheral perfusion was related to worse outcome, these parameters have never been used as target for hemodynamic therapy.

Objective: To study whether peripheral perfusion targeted fluid management (PPTFM) leads to less fluid administration, improved respiratory function and shorter mechanical ventilation.

Study design: The study is a pilot study and is designed as a randomized controlled trial. The study will be conducted as a single-center study at the Intensive Care of the Erasmus Medical Center.

Study population: We aim to include 40 adult patients who are admitted to the Intensive Care with hemodynamic instability (defined as mean arterial pressure < 65 mmHg and an arterial lactate concentration > 3.0 mmol/l) due to severe sepsis and septic shock.

Intervention: In the intervention group fluid management is targeted on peripheral perfusion parameters while in the control group fluid is administered in order to optimize cardiac output.

Main study parameters/endpoints: The main study endpoints are daily fluid balance and duration of mechanical ventilation.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There is a possible risk that in the treatment group the patients will remain hypovolemic. To ensure that this will not occur, fluids will be administrated in this group, irrespective of peripheral perfusion parameters, until cardiac index is 2,5 L/min/m2. Assessment of peripheral perfusion is performed with non-invasive optical techniques that impose no burden to the patient.

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Zuid-Holland
      • Rotterdam, Zuid-Holland, Netherlands, 3015 CE Rotterdam
        • Recruiting
        • ErasmusMC
        • Contact:
        • Principal Investigator:
          • Jasper v Bommel, MD,PhD
        • Sub-Investigator:
          • Michel v Genderen, Msc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All adult patients (>18 years) admitted to the intensive care with 1) hemodynamic instability due to severe sepsis, and 2) a mean arterial pressure < 65 mmHg and 3) an arterial lactate concentration > 3.0 mmol/L will be considered for participation

Exclusion Criteria:

  • moribund.
  • severe coagulation disorder (contraindication for central venous catheter placement).
  • severe peripheral vascular disease (interfering with peripheral perfusion measurement).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Control
The fluid management algorithm of the control group is based on the standard care procedure of our ICU as recommended in guidelines: the patient's fluid status is assessed by performing a fluid challenge with a bolus of 250 ml colloids. When the patients is fluid responsive (i.e. showing an increase in stroke volume > 10% ) he will receive an additional bolus of 250 ml of colloids. After each fluid challenge, patients will be revaluated for fluid responsiveness to access need of further fluid administration.
EXPERIMENTAL: PPTFM
The fluid management algorithm of the intervention group uses identical therapy (i.e. fluids) yet targeted at different endpoints (i.e. peripheral perfusion parameters). After evaluation of peripheral perfusion, only patients with a "bad peripheral perfusion" (i.e. 3 out of 4 criteria considered as bad) will receive a fluid challenge, the same way as in the standard care procedure (i.e. bolus of 250 ml of fluid). After each fluid challenge, patients will be re-evaluated for peripheral perfusion to access further need in fluid challenges. To ensure that no hypovolemia will occur in the intervention group, fluid will be administered irrespectively of peripheral perfusion parameters, if cardiac index falls below a value of 2,5 L/min/m2.
Peripheral Perfusion Targeted Fluid Management
Other Names:
  • CRT
  • PFI
  • delta Temp
  • StO2

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fluid balance during Intensive Care Unit stay
Time Frame: untill 72 hours after admission
Total and daily fuid balance for a maximal time period of 72 hours
untill 72 hours after admission

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CRT (Capillary refill time)
Time Frame: Within 72 hours after admission
Parameter of peripheral perfusion
Within 72 hours after admission
Systemic hemodynamic variables
Time Frame: Untill 72 hours after admission to the ICU
  • Heart Rate
  • Mean Arterial Pressure
  • Cardiac Index
  • Cardiac output
  • Stroke Volume
  • Central Venous Pressure
  • Systemic Vascular Resistance
Untill 72 hours after admission to the ICU
Respiratory function
Time Frame: Untill 72 hours after admission to the ICU
  • FiO2
  • PEEP
  • Breathing Frequency
  • pCO2
  • pO2
Untill 72 hours after admission to the ICU
PFI (Peripheral Flow Index)
Time Frame: Untill 72 hours after ICU admission
Parameter of peripheral perfusion
Untill 72 hours after ICU admission
Tskindiff (Forearm-to-Fingertip temperature skin difference)
Time Frame: Untill 72 hours after ICU admission
Parameter of peripheral perfusion
Untill 72 hours after ICU admission
StO2 (Peripheral tissue oxygenation)
Time Frame: Untill 72 hours after ICU admission
Parameter of peripheral perfusion
Untill 72 hours after ICU admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Michel E Genderen, Drs, Erasmus Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2011

Primary Completion (ANTICIPATED)

January 1, 2014

Study Completion (ANTICIPATED)

January 1, 2014

Study Registration Dates

First Submitted

July 7, 2011

First Submitted That Met QC Criteria

July 18, 2011

First Posted (ESTIMATE)

July 19, 2011

Study Record Updates

Last Update Posted (ESTIMATE)

January 6, 2014

Last Update Submitted That Met QC Criteria

January 3, 2014

Last Verified

January 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Subscribe